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The multi-kinase inhibitor dasatinib is used for treatment of imatinib-resistant chronic
myeloid leukemia, but is prone to induce microvascular dysfunction. In lung this
can manifest as capillary leakage with pleural effusion, pulmonary edema or even
pulmonary arterial hypertension. To understand how dasatinib causes endothelial
dysfunction we examined the effects of clinically relevant concentrations of dasatinib
on both human pulmonary arterial macro- and microvascular endothelial cells (ECs).
The effects of dasatinib was compared to imatinib and nilotinib, two other clinically
used BCR/Abl kinase inhibitors that do not inhibit Src. Real three-dimensional
morphology and high resolution stiffness mapping revealed softening of both macro-
and microvascular ECs upon dasatinib treatment, which was not observed in response
to imatinib. In a dose-dependent manner, dasatinib decreased transendothelial electrical
resistance/impedance and caused a permeability increase as well as disruption of tight
adherens junctions in both cell types. In isolated perfused and ventilated rat lungs,
dasatinib increased mean pulmonary arterial pressure, which was accompanied by a
gain in lung weight. The Rho-kinase inhibitor Y27632 partly reversed the dasatinib-
induced changes in vitro and ex vivo, presumably by acting downstream of Src.
Co-administration of the Rho-kinase inhibitor Y27632 completely blunted the increased
pulmonary pressure in response to dasatinib. In conclusion, a dasatinib-induced
permeability increase in human pulmonary arterial macro- and microvascular ECs might
explain many of the adverse effects of dasatinib in patients. Rho-kinase inhibition might
be suitable to ameliorate these effects.
Keywords: endothelial cells, paracellular permeability, dasatinib, Rho-kinase, pulmonary arterial hypertension,
endothelial elasticity
INTRODUCTION
Dasatinib is a second generation BCR/Abl tyrosine kinase inhibitor (TKI) approved for first-and
second-line use in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-
positive acute lymphoid leukemia. It is also being evaluated as a therapy for numerous solid cancer
types. Besides dasatinib, other TKIs such as imatinib and nilotinib have been approved for the
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treatment of CML. These TKIs share common targets such as
BCR/Abl, platelet derived growth factor receptor (PDGFR) and
c-kit. However, dasatinib is also a potent Src tyrosine kinase
(SrcTK) inhibitor (Lombardo et al., 2004; Rix et al., 2007).
Due to the differences in the pharmacological profile, each
TKI has a unique side-effect profile (Pasvolsky et al., 2015).
Dasatinib therapy has been associated with the risk of partially
reversible pulmonary arterial hypertension (PAH), with an
estimated incidence of 0.45% (Montani et al., 2012, 2013; Orlandi
et al., 2012; Sano et al., 2012). To date, more than 100 cases
of dasatinib-induced PAH have been submitted for European
pharmaceutical vigilance. PAH is a highly morbid and often
fatal disease characterized by progressive pulmonary vascular
obstruction. PAH affects all layers of the pulmonary arterial
wall (Galie et al., 2009; Dayeh et al., 2016). Dasatinib-induced
potassium channel inhibition in pulmonary arterial smooth
muscle cells may play a key role in the development of PAH,
however, adverse effects on endothelial cells (ECs) cannot be
excluded (Nagaraj et al., 2013; Olschewski et al., 2014; Guignabert
et al., 2016).
Dasatinib therapy may also induce microvascular leakage
resulting in pleural effusion, lung and peripheral edema (Han
et al., 2013; Latagliata et al., 2013; Dong et al., 2016; Kreutzman
et al., 2017). Pleural effusion affects 10–35% of the treated
patients, and in 78% the effusion is classified as exudative
(with lymphocytic predominance). Dasatinib could affect barrier
function through several different mechanisms. Since BCR/Abl
has been shown to regulate pulmonary endothelial barrier
function (Dudek et al., 2010; Wang et al., 2011), dasatinib may
induce dysfunction by the inhibition of BCR/Abl. However,
both PAH and pleural effusion are much stronger associated
with dasatinib than with nilotinib or imatinib treatment,
which suggests that unique actions of dasatinib may cause
endothelial leakage and vasoconstriction. Inhibition of potassium
channels likely explains pulmonary vasoconstrictive effects but
not endothelial leakage.
We investigated the effects of dasatinib on the barrier
function of pulmonary micro- and macrovascular ECs, using
primary human pulmonary microvascular ECs (HMVEC-L)
and pulmonary artery ECs (HPAEC) and employed a number
of different cellular and functional readouts. We found that
dasatinib but not imatinib or nilotinib caused significant
endothelial leakage, associated with Src inhibition and secondary
activation of ROCK signaling. We confirmed our in vitro results
in the isolated perfused rat lung model.
MATERIALS AND METHODS
Cell Culture and Treatments
Human pulmonary microvascular ECs and human pulmonary
artery ECs were purchased from Lonza (Allendale, NJ,
United States) and were cultured according to the manufacturer’s
instructions. In our experiments, we used HMVEC-Ls from four
different donors and HPAECs from two different donors. The
endothelial-specific media (VascuLife R© Basal Medium, Lifeline
Cell Technology in the case of HPAEC and EBM-2, Lonza for
HMVEC-L) was changed every third day. Cells used in the
experiments were between passages five and nine. Confluent
cultures were washed with serum-free VascuLife medium, and
incubated in the same serum-free medium for 2 h prior to
15 min treatments for western-blot analyses. Transendothelial
electrical resistance (TEER), permeability and gene expression
measurements were performed in VascuLife medium containing
2% FBS (Sigma). The following concentrations were used for
cell treatments: dasatinib (Selleck Chemicals) 1 nM, 10 nM,
and 100 nM; imatinib (Selleck Chemicals) 5 µM; nilotinib
(Selleck Chemicals) 100 nM; PP2 (Selleck Chemicals) 10 µM;
Y-27632 (Tocris) 10 µM and fasudil (Tocris) 10 µM. All
chemicals were dissolved in dimethylsulfoxide (DMSO) resulting
in 0.1% final concentration during treatments. For control
experiments, cells received the same amount of DMSO in
medium.
Transendothelial Electrical Resistance
(TEER) Measurements
A computer-controlled device (CellZScope R©, nanoAnalytics,
Muenster, Germany) was used to measure TEER of endothelial
monolayers. HMVEC-L cells were cultured until confluence on
collagen/fibronectin-coated semipermeable filter inserts (0.4 µm
pore size, 0.33 cm2, Costar Corning Transwell Clear). Baseline
TEER was measured for 1 h before experiments, followed by
application of different treatments for up to 24 h.
Cell Index (CI) Measurements
Cell index (CI) was calculated from real-time impedance data
acquired in ACEA’s xCELLigence R© real-time cell analysis (RTCA)
instrument. HMVEC-L and HPAEC cells were cultured on
collagen-coated 96-well E-plates until the CI values reached the
plateau. Treatments were applied and changes of endothelial
barrier properties were monitored for 12 h.
Permeability Measurements
Endothelial barrier permeability to 4 kDa FITC-dextran (Sigma)
was assessed in phenol red-free VascuLife R© Basal Medium
(Lifeline Cell Technology) supplemented with 2% FBS (Sigma).
After 24 h treatment, medium was removed and 200 µg/ml
4 kDa FITC-dextran containing media was added in the
upper compartments. Cultures were incubated at 37◦C for
30 min with gentle shaking and samples were collected
from the lower compartment. FITC-dextran concentration of
the samples was measured using a fluorescent microplate
reader (FLUOstar Optima, BMG Labtechnologies, Offenburg,
Germany) with an excitation wavelength of 485 nm and an
emission wavelength of 520 nm specific for FITC-dextran.
Permeability coefficients (P) were calculated by the following
equation:
P = dQ
dT × A× C0
(dQ: transported amount, dT: incubation time, A: surface of filter,
C0: initial concentration in the luminal compartment).
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The values for empty filter inserts (Pfilter) were subtracted from
the values of the endothelial monolayers (Ptotal) obtaining the real
value for the endothelial monolayer (Pe) using the formula:
1
Pe
= 1
Ptotal
− 1
Pfilter
Immunofluorescence Studies
For immunofluorescence studies, HMVEC-L and HPAEC cells
were cultured on collagen/fibronectin-coated filter inserts.
Endothelial monolayers were fixed using a mixture of ice-cold
ethanol:acetic acid (95:5 v/v) for 10 min and then washed
three times for 5 min in PBS. After blocking with 3% bovine
serum albumin (BSA, Sigma) for 30 min, inserts were incubated
with primary antibodies against VE-cadherin (Cell Signaling
Technology) or ZO-1 (Invitrogen), nuclei were counterstained
with Hoechst33342 (Sigma). The staining was visualized using
Cy3- or Cy2-conjugated secondary antibodies (Jackson Immuno
Research) diluted in 1% BSA-containing PBS, and washed three
times for 5 min in PBS. Filter inserts were mounted in anti-
fading embedding medium (Fluorogel, Electron Microscopy
Sciences, Hatfield) and studied using a Nikon Eclipse TE2000U
photomicroscope (Tokyo, Japan) connected to a digital camera
(Spot RT KE, Diagnostic Instruments, Sterling Heights, MI,
United States).
Immunofluorescence images were quantified using the ImageJ
software (version 1.51n, NIH). We measured the mean intensity
of VE-cadherin immunofluorescence staining using the polygon
selection tool to define the cell junctions. In the case of ZO-1
tight junctional protein, we selected the cells by freehand
selection tools and then measured the continuity of the
immunofluorescence staining.
Western-Blot Analyses
Cells were lysed in ice-cold lysis radioimmune precipitation
buffer (20 mM Tris, 150 mM NaCl, 0.5% Triton X-100, 1%
sodium deoxycholate, 0.1% sodium dodecyl sulfate, 1 mM
sodium van date, 10 mM NaF, 1 mM EDTA, 1 mM Pefabloc R©)
and incubated on ice for 30 min. Lysates were clarified by
centrifugation at 10,000 × g for 10 min at 4◦C. Protein
concentration was determined with the bicinchoninic acid
(BCA) method (Pierce, Rockford, IL, United States). Proteins
were electrophoresed with standard denaturing SDS-PAGE
procedures and blotted on PVDF (Bio-Rad) or nitrocellulose
(Bio-Rad) membranes. Blocking the non-specific binding
capacity of the membranes was carried out at room temperature
for 30 min in TBS-T (Tris buffered saline with 0.1% Tween 20)
containing either 5% casein (non-fat milk powder) or 3% BSA.
Membranes were incubated with primary antibodies against
total c-Src, pSrc (Y416), or non-phosphorylated (Y416)-Src (Cell
Signaling) or β-actin (Sigma). After washing the membranes
three times for 10 min in TBS-T, the blots were incubated with
the secondary antibodies diluted in TBS-T, then washed again
three times for 10 min in TBS-T. The immunoreaction was
visualized using Immobilon Western Chemiluminescent HRP
Substrate (Millipore, Billerica, MA, United States) on X-ray film
(Alga, Mortsel, Belgium).
Atomic Force Microscopy (AFM)
Measurements
All experiments were carried out with an Asylum Research
MFP-3D atomic force microscope (Asylum Research, Santa
Barbara, CA, United States; driving software IgorPro 6.32A,
Wavemetrics), situated on the top of a Zeiss Axiovert 200
type optical microscope. The experiments were performed with
overall gold coated silicon nitride rectangular cantilevers holding
a V-shaped tip (BL-RC150VB Olympus, Optical Co. Ltd.). The
cantilevers have a nominal spring constant of 30 pN/nm, resonant
frequency of 25 kHz in air, which drops to 10 kHz in liquid. The
spring constant of each of the used cantilevers were determined
each time by thermal calibration (Hutter and Bechhoefer, 1993;
Higgins et al., 2006; Sader et al., 2012). During measurements
cells were kept in Leibovitz’s medium (Gibco, Thermo Scientific)
containing 2% FBS at 37◦C for maximum 3 h. Images from
an area of 60 µm × 60 µm having 256 lines × 256 points
were recorded in alternate contact mode using closed loop with
a speed of 90 µm/s. Trace and retrace images were recorded
and compared for validation, no considerable differences were
found. Probing any material with a hard indenter (AFM tip)
leads to the theory of indenting an elastic half-space with a stiff
object, based on the work of Hertz (1881) and Sneddon (1965)
later modified for AFM tips (Mathur et al., 2001). This theory
is used for indentation tests, regardless of length scale. Elastic
characterization was based on calculating the sample’s elastic
modulus from each force curve (Varga et al., 2016).
During recording a single force curve, the tip is brought into
contact with the top (indentation below 500 nm) layer of the cells.
Force curves were recorded at constant loading speed (8 µm/s)
and sampling frequency (2 kHz). Total force distance was kept
at 3 µm with maximum load of 300 pN. 32 lines × 32 points
maps (force volume) were recorded at each selected area of 60
µm × 60 µm, data collection for one image was approximately
15 min. Values for elasticity were extracted with the microscope’s
driving software, implementing the above mentioned models and
assumptions.
Ex Vivo Experiments on Isolated
Perfused and Ventilated Rat Lungs
All animal care and experimental procedures complied with EU
and Austrian regulations and were approved by and reported
to the Institutional Animal Care and Use Committee (BMWF,
Austria and Medical University of Graz, Graz, Austria). All
measures were taken to keep animal suffering to a minimum.
Seventeen male Sprague-Dawley rats (Janvier, Saint Berthevin,
France), weight 350± 112 g (mean± SD) were used in this study.
Rats were sacrificed by an overdose of ketamine (200 mg/kg
b.w.) and xylazine (17 mg/kg b.w., exsanguinated, the heart and
lung removed enblock and mounted in IPL-2 HSE Harvard
Apparatus (March-Hugstetten, Germany). Lungs were perfused
through the pulmonary artery at constant flow with 37◦C sterile
Krebs-Henseleit buffer containing 2% BSA (Sigma A9647), 0.1%
glucose, 0.1% Hepes, 24 mM NaHCO3 and ventilated with
negative pressure in a closed chamber with a tidal volume of
∼12.4 ml/kg b.w., an end-expiratory pressure of −2 cm H2O
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and a respiratory rate of 60 breaths/min. Hyperinflation (−22
to −24 cm H2O) was performed at 1-min intervals. Lungs
were initially acclimatized with one-way perfusion (∼45′) and
then switched to recirculation (total volume 200 ml). After
20′ equilibration period, dasatinib (100 nM) was added to the
perfusate (Timepoint 0’). In a subgroup of rats, Y27632 (10 µM)
was added to the perfusate 20’ prior to dasatinib. The pH of
the perfusate was continuously monitored and adjusted to pH
7.3 with CO2. Changes in mean pulmonary arterial pressure
and weight (oedema formation) were continuously recorded over
a 150-min period. Data are presented as weight/mPAP change
compared to the 0’ timepoint. Data were compared using a
two-way ANOVA.
Statistical Analysis
Data analysis was performed using GraphPad Prism software
(version 7.0). The statistical tests are presented at each result and
given in the figure legends.
RESULTS
Dasatinib Alters Barrier Properties of
Pulmonary Micro- and Macrovascular
Endothelial Cells
We first evaluated the dasatinib effects on endothelial barrier
properties by measuring the electrical impedance of cells exposed
to clinically relevant concentrations of dasatinib. For comparison
imatinib and nilotinib were also used. Like dasatinib, imatinib,
and nilotinib are potent BCR/Abl kinase inhibitors, but less prone
to induce PAH or lung edema. In response to 100 nM dasatinib,
TEER of microvascular pulmonary endothelial (HMVEC-L) cells
dropped significantly within 1 h and this effect lasted up to 24 h
(Figure 1A). Imatinib at 5 µM had a lower and transient effect
on changes in the TEER of HMVEC-L, while nilotinib at 100
nM did not significantly alter the endothelial barrier properties
in comparison to control cells (Figure 1A).
Since macrovascular ECs do not form such a tight barrier
as the microvascular endothelium in the lung, measuring the
TEER of cells cultured on semipermeable filter inserts was
complemented with measuring the CI of cells cultured on
gold electrodes. We applied the same treatments (100 nM
dasatinib, 100 nM nilotinib, 5 µM imatinib) in parallel to both
micro- (Figure 1B) and macrovascular (HPAEC) (Figure 1C)
ECs and measured in real-time the impedance of the cells
reflected by the CI. We observed a rapid decrease of the CI
of both HMVEC-L and HPAEC cells after dasatinib application
(Figures 1B,C). This effect was long-lasting (up to 24 h),
whereas imatinib only induced a transient CI decrease in
HPAEC cells. After 24 h exposure the permeability of HMVEC-L
(Figure 1D) and HPAEC (Figure 1E) to 4 kDa FITC-dextran was
determined. The permeability coefficient reflects the paracellular
diffusion of the fluorescent dye, which increased significantly
in response to 100 nM dasatinib in both microvascular
and macrovascular endothelial monolayers (Figures 1D,E).
Neither imatinib, nor nilotinib facilitated the transfer of the
fluorescent marker from the apical to the basolateral side of the
cells.
The Dasatinib-Induced Pulmonary
Endothelial Injury Is Dose-Dependent
The TEER-decreasing effect of dasatinib on HMVEC-L cells
proved to be strongly concentration-dependent, with the highest
concentration having the most accentuated effect (Figure 2A). In
accordance with the TEER changes, FITC-dextran permeability
assay also showed a concentration- dependent increase in
response to dasatinib. These concentration-dependent barrier
disrupting effects of dasatinib were observed in both micro-
and macrovascular ECs (Figure 2B). Dasatinib-induced
impedance and permeability changes suggested the involvement
of the inter-endothelial junctions. This was confirmed by
immunofluorescence staining of the junctional protein VE-
cadherin. Treatment of ECs with either 1 nM or 10 nM dasatinib
exhibited minimal effects on the distribution of VE-cadherin
in HMVEC-L or HPAEC cells. However, the clinically relevant
concentration of dasatinib (100 nM) resulted in significant
loss of the continuous distribution of VE-cadherin, indicating
interendothelial junctional disruption (Figures 3A,B). Moreover,
we observed formation of inter-endothelial gaps, probably
due to changes in the adhesion of the cells to the substrate
(Figure 3A).
At these concentrations, no apoptotic or cytotoxic effects
of dasatinib were detected in the ECs after 24 h of treatment
(Supplementary Figures S1A,B). Based on these results, all future
experiments were performed with 100 nM of dasatinib.
Dasatinib Induces Nanomechanical
Changes in Pulmonary Endothelial Cells
High resolution three dimensional images were recorded in
tapping mode on confluent HMVEC-L monolayers prior to and
after 30 min of administration of dasatinib. Dasatinib induced
superficial cytoskeletal reorganization and cell morphology
alteration which could not be seen in case of the vehicle control
(Supplementary Figure S2). Similar results were obtained for
HPAEC cells (data not shown). Apparent Young’s modulus was
calculated using the modified Hertz model for each recorded
curve. Representative reconstructed pseudo-colored elasticity
maps recorded prior and after dasatinib treatment or medium
change alone are shown for HMVEC-L (Figures 4A,C) and
HPAEC (Figures 4B,D) cells, respectively. In both cases, there
was a remarkable increase in elasticity in response to dasatinib
as compared to control. As no cell compartment specificity
was observed in any case, averages from whole reconstructed
maps were calculated for comparison. In order to visualize the
dynamics of elasticity change for both cell types, average values
from whole maps were calculated and plotted against time. To
properly compare the changes induced by different treatments,
all values were normalized to initial (pre-treatment) values.
Figures 4E,F show the time evolution of the relative elasticity
change calculated from five parallel measurements for each cell
type and treatment. Dasatinib treatment reduced the stiffness of
both HMVEC-L (Figure 4E) and HPAEC (Figure 4F) cells as
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FIGURE 1 | Dasatinib, but not imatinib or nilotinib, alters barrier properties of HMVEC-L and HPAEC cells. HMVEC-L or HPAEC cells were treated with clinically
relevant concentrations of dasatinib (100 nM), imatinib (5 µM), nilotinib (100 nM) or vehicle (ctrl: 0.1% DMSO). Cell impedance (transendothelial electrical
resistance/TEER or cell index/CI) was followed for 24 h. TEER of HMVEC-L cells was normalized to values before treatments (TEER0) (A). CI of HMVEC-L and
HPAEC cells were normalized to values before treatments (CI0) (B,C). Permeability of HMVEC-L and HPAEC cells to 4 kDa FITC-dextran was measured after 24 h
exposure to TKIs (D,E). Data analysis was done by two-way (A–C) or one-way (D,E) ANOVA with Tukey post hoc test. Values are presented as mean ± SD;
∗p < 0.05, ‡p < 0.01, +p < 0.001, •p < 0.0001 compared to ctrl. Representative results of three (N = 3, A,D), five (N = 5, B), four (N = 4, C) or two (N = 2, E)
independent experiments are shown.
compared to control. Effect of imatinib treatment on the cells’
elasticity appeared to be similar to control.
Rho-Kinase (ROCK) Inhibition Attenuates
Dasatinib-Induced Endothelial Barrier
Dysfunction
ROCK inhibition had no significant effect on the dasatinib-
induced impedance drop of HMVEC-L cells (Figure 5A). On
the other hand, co-treatment with Y27632 or fasudil significantly
attenuated the dasatinib-dependent CI decrease of HPAEC cells
(Figure 5B). The dasatinib-induced permeability increase of
HMVEC-L cells to FITC-dextran was moderately decreased
in the presence of Y27632 (Figure 5C). However, Y27632
significantly reduced hyperpermeability of HPAECs resulting
from dasatinib treatment (Figure 5D).
Since ROCK inhibition during dasatinib treatment was
beneficial for endothelial barrier properties, we examined the
effect of Y27632 on the localization of VE-cadherin and ZO-1
junctional proteins. Y27632 ameliorated the dasatinib-induced
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FIGURE 2 | Dasatinib-induced changes in endothelial TEER (A) and permeability (B) are concentration-dependent. HMVEC-L and HPAEC cells were exposed to
dasatinib (das: 1 nM, 10 nM, or 100 nM) or vehicle (ctrl: 0.1% DMSO) for 24 h. Two-way ANOVA test was performed with Tukey post hoc multiple comparison test.
Values are presented as mean ± SD; ∗p < 0.05, ‡p < 0.01, +p < 0.001, •p < 0.0001 compared to ctrl. Representative results of three independent experiments
(N = 3) are shown.
loss of endothelial junctional integrity in HMVEC-L cells, as
seen both for VE-cadherin and ZO-1 proteins (Figures 6A–C).
In HPAEC the difference between dasatinib-treated and
dasatinib+Y27632-treated cells was even more pronounced,
suggesting a particularly beneficial effect of ROCK inhibition
(Figures 7A–C).
Despite the beneficial effect on the junctions, treatment of ECs
with Y27632 did not overcome the cellular stiffness-decreasing
effect of dasatinib, as measured with AFM (data not shown).
Dasatinib-Dependent Src Inhibition
Might Contribute to the Disruption of
Pulmonary Endothelial Junctional
Complexes
Since we observed formation of inter-endothelial gaps in
response to dasatinib, we presumed that dasatinib-induced
inhibition of Src activity might cause endothelial dysfunction.
First, we examined the expression of Src kinases by RT-PCR
in HMVEC-L cells. All Src tyrosine kinase mRNA isoforms
(c-Src, Yes, Lyn, Fyn, Lck, Frg) were present in these cells,
c-Src and Lyn were strongly detected, while Fyn and Yes were
detected but weaker. Expression of Lrg and Lyn could nor
reliably be detected (Supplementary Figure S1C). HMVEC-L
were treated with 100 nM dasatinib for 15 min. Dasatinib
markedly reduced Src activation (phosphorylation on Tyr416)
whereas the administration of the ROCK inhibitor (Y27632) had
no effect on Src phosphorylation (Supplementary Figures S1D,E).
In order to investigate if Src inhibition causes barrier
dysfunction in pulmonary ECs, we compared the effects of
dasatinib with the Src-specific inhibitor PP2 on TEER and
permeability of HMVEC-L monolayers. Similar to dasatinib,
PP2 caused a significant decline in the TEER values and an
increase in permeability compared to control (Supplementary
Figures 3A,B). The permeability increasing effect of PP2 was
reversed by Y27632 (Supplementary Figure 3B). In line with the
effects of dasatinib, PP2 disrupted the junctional complex of both
micro- and macrovascular EC, as shown by decreased junctional
staining of ZO-1 and gaps in the monolayers (Supplementary
Figure 3C).
Dasatinib Causes Pulmonary Pressure
Increase and Edema Formation in Rat
Lungs
Our in vitro data were complemented with measurements
of pulmonary vascular pressure and edema formation in
isolated perfused rat lungs. As indicated on Figures 8A,B,
dasatinib caused an increase in the mean pulmonary arterial
pressure, which could be reversed by co-administration of the
ROCK inhibitor Y27632. Elevated pulmonary arterial pressure
was accompanied by a gain in the lung weight over time
(Figures 8C,D). However, dasatinib-dependent edema formation
was not prevented by Y27632.
DISCUSSION
The TKIs: imatinib, nilotinib, and dasatinib have been approved
for the treatment of CML and primarily target the BCR/Abl
kinases and c-kit. Dasatinib, but not imatinib or nilotinib, also
potently inhibits the tyrosine kinases of the Src family (c-Src,
Yes, Lyn, etc.) (Rix et al., 2007; Weisberg et al., 2007). c-Src
has a central role in the regulation of endothelial permeability
(Komarova et al., 2017). Dasatinib was shown to effectively
inhibit Src in a concentration of 4-9nM (Rix et al., 2007; Shi et al.,
2012), while imatinib or nilotinib had no effects up to 10µM
(Chislock and Pendergast, 2013) or 4.5 µM (Manley et al., 2010)
concentrations.
Off-target effects of dasatinib may be largely responsible for its
adverse effects, including PAH, pleural effusion and pulmonary
edema. Pleural effusion was characterized by lymphocytosis,
suggesting an inflammatory response (Bergeron et al., 2007).
PAH could be explained, at least partially, by Src inhibition,
causing inactivation of an important two pore domain potassium
channel in pulmonary artery smooth muscle cells (PASMCs;
Nagaraj et al., 2013), while dasatinib-induced endothelial
dysfunction may be independent of Src inhibition. Guignabert
et al. (2016) suggested increased ROS production, apoptosis, and
elevated expression of endothelial adhesion molecules ICAM-1,
VCAM-1, and E-selectin in pulmonary artery ECs as underlying
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FIGURE 3 | Dasatinib disrupts the junctional complex of HMVEC-L and HPAEC cells in a concentration-dependent manner. HMVEC-L and HPAEC cells were
exposed to dasatinib (1 nM, 10 nM, or 100 nM,) or vehicle (ctrl: 0.1% DMSO). Cells were fixed and probed with anti-VE-cadherin antibody (red), nuclei were
counterstained with Hoechst 33342 (blue). (A) Representative images of two independent experiments are shown. (B) Quantification of the immunofluorescence
staining intensity. Arrows indicate loss of junctional protein staining, while arrowheads indicate the gaps between cells. Data analysis was done by one-way ANOVA
with Tukey post hoc test. Values are presented as mean ± SD; ∗p < 0.05, +p < 0.001, •p < 0.0001 compared to ctrl (N = 6).
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FIGURE 4 | Dasatinib induces changes in elasticity of HMVEC-L and HPAEC cells, as measured by AFM. Pseudo-colored reconstructed elasticity (each point
showing the apparent Young’s modulus) maps of HMVEC-L (A,C) and HPAEC (B,D) cells prior to and 45 min after treatment with vehicle (0.1% DMSO) containing
medium (med) as control or 100 nM dasatinib (das), respectively. Charts (E,F) represent average values of five parallel sets. Values were normalized to the
pre-treatment state of each set. Cells were treated with dasatinib (das, 100 nM), imatinib (im, 5 µM; data not shown) or vehicle (0.1% DMSO) containing medium
(ctrl) for both studied cell types.
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FIGURE 5 | Rho-kinase inhibition partially reverses dasatinib-induced alterations in the barrier properties of HMVEC-L and HPAEC cells. Cells were treated with
dasatinib (100 nM), dasatinib and Y27632 (10 µM), Y27632, dasatinib and fasudil (10 µM) or vehicle as control (ctrl: 0.1% DMSO) and CI was assessed (A,B).
Permeability changes of HMVEC-L (C) and HPAEC (D) monolayers was determined after 24 h. Statistical analysis was performed using two-way ANOVA test (A,B)
or one-way ANOVA (C,D) with Tukey post hoc multiple comparison; ∗p < 0.05, ‡p < 0.01, +p < 0.001, •p < 0.0001. Representative images of five (N = 5, A), four
(N = 4, B) or three (N = 3, C,D) independent experiments are shown.
mechanisms. Indeed, increased levels of the adhesion molecules
were found in the serum of CML patients (Guignabert et al.,
2016). In our study, we induced endothelial dysfunction by
exposing human pulmonary macro- and microvascular ECs to
clinically relevant concentrations of dasatinib.
After oral administration of 70 mg dasatinib twice daily
for CML, the plasma peak concentration (Cmax) of dasatinib
reaches ∼90 nM (Weisberg et al., 2007). Therefore, we treated
pulmonary ECs up to a maximal concentration of 100 nM and
assessed the effects on the barrier properties. In accordance with
previous data, human pulmonary arterial ECs (HPAECs) have
lower relative barrier properties compared to the pulmonary
microvascular endothelium (HMVEC-L, Mehta and Malik,
2006; Stevens et al., 2008). Dasatinib treatment increased the
permeability of both micro- and macrovascular ECs in a dose-
dependent manner and induced a marked decrease in cell
impedance. In contrast, the effects of imatinib or nilotinib were
minimal. Integrity of the endothelial barrier relies on tight and
adherens junctions at cell-cell contacts. The main component of
endothelial adherens junctions is VE-cadherin, which is a key
regulator of paracellular permeability (Dejana et al., 2009). ZO-1
is a cytoplasmic junctional protein involved in the formation
of both tight and adherens junctions (Fanning and Anderson,
2009). Disappearance of VE-cadherin or ZO-1 from intercellular
junctions may lead to barrier disruption (Tornavaca et al., 2015).
Our results suggest that both VE-cadherin and ZO-1 junctional
proteins disappeared from intercellular junctions in micro- and
macrovascular endothelial monolayers exposed to dasatinib.
Junctional complexes responsible for the maintenance of
barrier properties are connected to the actin cytoskeleton.
Cellular responses to agents disrupting intercellular connections
or cytoskeletal remodeling can be detected by assessment of
the elastic properties of the cells. In order to monitor quick
mechanical changes in living cells, atomic force microscope offers
an outstanding resolution and precision (Birukova et al., 2009).
Using this technique, we followed the changes in elasticity of ECs
upon dasatinib or imatinib treatment. We demonstrated that only
dasatinib caused softening of both micro- and macrovascular
cells. This stiffness decreasing effect may reflect disruption of
intercellular junctions and loss of barrier function, as previously
shown in brain ECs exposed to hyperosmosis (Balint et al., 2007).
Rho GTPases belong to the main regulators of the actin
cytoskeleton. RhoA/ROCK signaling plays an important role
in endothelial barrier function through regulation of the
actin cytoskeleton. The activated RhoA/ROCK pathway impairs
endothelial barrier properties leading to increased paracellular
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FIGURE 6 | Rho-kinase inhibition partially protects against dasatinib-induced disassembly of endothelial junctions in HMVEC-L cells. Cells were treated with
dasatinib (100 nM), dasatinib and Y27632 (10 µM), Y27632 or vehicle (ctrl: 0.1% DMSO) for 1 h. Cells were fixed and probed with anti-VE-cadherin (red) or
anti-ZO-1 antibodies (green), nuclei were counterstained with Hoechst 33342 (blue). (A) Representative images of three independent experiments are shown.
(B) Quantification of the immunofluorescence staining intensity and (C) staining continuity. Arrows indicate loss of junctional protein staining, while arrowheads
indicate the gaps between cells. Data analysis was done by one-way ANOVA with Tukey post hoc test. Values are presented as mean ± SD; +p < 0.001,
•p < 0.0001 compared to ctrl (N = 4).
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FIGURE 7 | Disruption of endothelial junctions in HPAEC cells is partially ameliorated by simultaneous ROCK inhibition. Cells were treated with dasatinib (100 nM),
dasatinib and Y27632 (10 µM), Y27632 or vehicle (ctrl: 0.1% DMSO) for 2 h. Cells were fixed and probed with anti-VE-cadherin (red) or anti-ZO-1 antibodies (green),
nuclei were counterstained with Hoechst 33342 (blue). (A) Representative images of three independent experiments are shown (N = 3). (B) Quantification of the
immunofluorescence staining intensity (C) and staining continuity. Arrows indicate loss of junctional protein staining, while arrowheads indicate the gaps between
cells. Data analysis was done by one-way ANOVA with Tukey post hoc test. Values are presented as mean ± SD; ∗p < 0.05, ‡p < 0.01, •p < 0.0001 compared to
ctrl (N = 4).
permeability which could explain pleural effusion and edema
formation. Several studies suggest that activation of the
RhoA/ROCK pathway contributes to PAH (Nakanishi et al.,
2016) and that ROCK inhibitors are potential therapeutic agents
for PAH (Oka et al., 2008; Fujita et al., 2010). In addition to the
regulation of PASMCs, the GTPase RhoA plays primary role in
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FIGURE 8 | Rho-kinase inhibition ameliorates dasatinib-induced elevation of pulmonary artery pressure, but not lung weight changes/edema formation. Isolated
perfused rat lungs were exposed to dasatinib (100 nM), dasatinib and Y27632 (10 µM) or vehicle (CTRL) for 150 min. Changes in mean pulmonary artery pressure
(mPAP) (A) and lung weight (B) were followed in time. (C,D) Charts represent lung weight and mPAP change compared to the 0’ timepoint. Data analysis was done
by two-way ANOVA, with Bonferroni’s post hoc test, five animals/group. Values are presented as mean ± SD; ∗p < 0.05 as compared to control: CTRL, #p < 0.05
as compared to Das.
the regulation of endothelial barrier function and permeability.
During the development and progression of PAH, endothelial
dysfunction is a critical event. Behind the vascular pathology
observed in PAH there are changes of signaling mechanisms
regulating angiogenesis, endothelial-mesenchymal transition and
epigenetic regulation of ECs, which might lead to increased
endothelial permeability (Morrell et al., 2009; Good et al., 2015;
Ranchoux et al., 2018). The endothelial dysfunction leads to
an imbalance of endothelial and smooth muscle cell crosstalk
(Morrell et al., 2009; Nogueira-Ferreira et al., 2014). Interestingly,
Src blocks the RhoA/ROCK pathway through p190RhoGAP and
through phosphorylation of ROCK (Lee et al., 2010). Therefore, it
is plausible that the barrier disruptive effect of dasatinib might be
due to its inhibitory effect on Src, resulting in ROCK activation.
Accordingly, Y27632, a potent ROCK inhibitor ameliorated
dasatinib-induced disassembly of VE-cadherin and ZO-1 and the
increase in the permeability of endothelial monolayers.
Recently, dasatinib has been shown to induce ROCK-
dependent micro- and macrovascular endothelial dysfunction in
non-pulmonary ECs. Dasgupta et al. (2017) used human dermal
microvascular ECs to show that dasatinib increases endothelial
permeability via the Rho-ROCK-MLC (myosin light chain)
pathway. Moreover, dasatinib affected tyrosine phosphorylation
of p130cas, paxillin, and vinculin, whereas imatinib had no
effect on the phosphorylation levels of these proteins. The
authors suggested that dasatinib by disrupting the inhibition of
RhoA by integrins, promotes activation of RhoA/ROCK pathway,
which results in endothelial barrier damage (Dasgupta et al.,
2017). Kreutzman et al. (2017) showed that dasatinib causes
a profound, reversible and dose-dependent disorganization of
HUVEC (human umbilical vein EC) monolayers and that
intraperitoneal administration of dasatinib induced intestinal
vascular leakage in mice. The molecular mechanisms involved
ROCK activation, MLC phosphorylation and activation of non-
muscle myosin II. Therefore, involvement of ROCK in dasatinib-
induced endothelial dysfunction seems to be important in the
whole body, and not only in the lung.
In our study, ROCK inhibition-dependent reduction in
dasatinib-induced barrier disruption was more pronounced in
pulmonary macrovascular than in pulmonary microvascular
ECs, as shown by immunofluorescence staining of junctional
proteins, permeability measurements and even more
by impedance measurements. Therefore, amelioration
of dasatinib complications by ROCK inhibition might
be more beneficial in macrovascular pulmonary areas.
Accordingly, in isolated perfused and ventilated rat lungs,
acute co-administration of the ROCK inhibitor attenuated
the dasatinib-induced elevation of pulmonary artery pressure,
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but had no effects on the weight gain (edema formation)
of the lung. In contrast, long-term ROCK inhibition was
recently shown to reduce dasatinib-induced Evans blue
extravasation in the mouse lung (Dasgupta et al., 2017).
Furthermore, in the ROCK1-deficient mouse, dasatinib-induced
pulmonary microvascular permeability was reduced to the
levels seen in wild type controls. This suggests that long-
term ROCK-inhibition might be also effective in amelioration
of the pulmonary microvascular dysfunction induced by
dasatinib.
According to our data and results from previous studies,
the effect of dasatinib on pulmonary ECs may contribute
substantially to the pulmonary adverse effects of the drug.
Our data are consistent with a scenario in which dasatinib,
in pulmonary ECs, by inhibition of src, triggers a barrier
disruption that is partly mediated by ROCK, leading to
endothelial dysfunction and vascular leakage. The application
of a ROCK inhibitor might be beneficial in dasatinib-induced
adverse effects involving endothelial dysfunction and pulmonary
vasoconstriction.
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